Your Pharma Rep Quit Mid-Launch. Here's the 72-Hour Playbook.

Sara DelgadoSara Delgado
6 min read
Empty pharmaceutical sales territory desk with a closed laptop and a blank territory map during a product launch.

Your Pharma Rep Quit Mid-Launch. Here's the 72-Hour Playbook

Week 11 of a launch. The Dallas rep resigns on a Tuesday. By Friday, the VP had posted the req, called two recruiters, and scheduled a kickoff for a search he was told would take 60 days.

It took 94. I watched the whole thing. By the time the new rep finished onboarding, the launch window in that territory was gone. Prescribers who tried the drug early and had questions got silence for three months. Two of the biggest writers in the territory went back to the competitor. Not because the product failed. Because nobody was there.

A launch vacancy is not a normal vacancy

Companies treat every empty territory the same way. Post the req, run the search, absorb the gap. For a mature product, that is expensive but survivable. The territory bleeds share slowly and the new rep wins most of it back.

A launch is different. You get one adoption window. Formulary reviews happen on a schedule. Early prescriber experiences are being formed right now, with or without you. A prescriber who has a bad first experience and no rep to fix it does not park the decision until you are staffed. They move on, and in about a dozen launch placements I have worked on, moved-on prescribers were the hardest accounts to reopen. Harder than never-tried.

The math is brutal. If a launch territory is supposed to build to $150K a month in new scripts by month twelve, a 94-day hole in months three through six does not cost you three months of revenue. It flattens the curve under every month after it. Model it yourself with your own launch plan; the number will be some multiple of the vacancy period. I broke down the general version of this in the cost of a bad hire, and a bad vacancy compounds the same way.

What companies do instead of solving it

They run the standard W2 search. Sixty to ninety days if nothing goes wrong. Something usually goes wrong.

They split the territory across two neighboring reps. On paper, coverage. In the field, each rep protects their own number first, and the orphaned territory gets the leftover 15% of their week. Splitting works for six weeks. Launches run longer than six weeks.

They fly in a manager. The DM covers the top ten accounts personally. Now you have a stretched manager, a half-covered territory, and a coaching vacuum for the rest of the district. I watched a district's other seven territories slip while the manager babysat the empty one.

The bridge rep

The fix that actually works: put an experienced contract rep in the territory inside two to three weeks, scoped to the launch window.

Contract pharma reps with therapeutic-area experience exist in nearly every major metro. Many carried launches at big pharma before going independent. They do not need six weeks of onboarding to sample-drop and run appointments; they need product training, the target list, and the message. In the placements I have been close to, a bridge rep was in the field between day 10 and day 21 from signature.

The economics are simpler than a CSO conversation. Hourly rate, defined term, 90 or 120 days with an option to extend. No 10-rep minimum, no implementation fee. And the structure keeps compliance clean: hourly, fair market value, set in advance, no per-script kicker. If someone proposes paying a bridge rep per script, that is an Anti-Kickback problem you are volunteering for, not a hustle incentive.

Run the W2 search in parallel. Take the full 90 days to find the right permanent rep instead of panic-hiring at day 45, which is how bad hires happen. Some companies end up converting the bridge rep. Fine. Either way the territory never went dark.

We documented one of these end to end in the vacant territory case study, and the general fast-staffing playbook lives in how to staff an empty territory fast.

The first 72 hours

Day one: pull the territory's trailing eight weeks of call activity and rank the accounts a vacancy will hurt first. Early adopters with open questions top the list.

Day two: decide who owns account triage this week. Somebody senior calls the top ten prescriber offices, tells them the transition is happening, and gives them a direct line. Silence is what kills you; sixty seconds of acknowledgment buys weeks of patience.

Day three: start both clocks. Req posted for the permanent search, and a contract staffing request out for the bridge. Not one or the other. Both.

Territory dark in the middle of a launch?

We place experienced contract pharma reps in vacant launch territories, typically in the field within two to three weeks. Tell us the territory and the timeline.

Get a bridge rep quote

Frequently Asked Questions

How fast can a contract rep realistically start?

Two to three weeks from signature in most metros, assuming your product training can run in under a week. The long pole is usually your own legal and credentialing process, not the rep. Companies that pre-approve a contractor MSA template cut a week off every future vacancy.

Won't prescribers notice they're getting a temporary rep?

Prescribers notice absence, not employment classification. A knowledgeable rep who shows up, answers clinical questions, and handles access issues is the brand's presence in that territory. Nobody asks to see a W2.

Should I just pay the bridge rep on commission to keep fixed costs down?

No. Volume-based pay to a 1099 rep on a federally reimbursed drug walks straight into Anti-Kickback Statute exposure (42 U.S.C. § 1320a-7b(b)). Hourly at fair market value is the structure the personal services safe harbor protects, and it is also what experienced contract reps expect.

What if the bridge rep outperforms and I want to keep them?

Ask. Some independents take the right W2 offer, especially attached to a launch they already own. Others value their independence and will extend the contract instead. Either outcome beats a dark territory.

Sara Delgado
Sara Delgado
Sara Delgado brings 8 years of pharmaceutical sales experience spanning primary care, specialty, and biologics. Having navigated everything from blockbuster product launches to patent cliffs, Sara has a deep understanding of what it takes to build lasting relationships with prescribers in a heavily regulated environment. She writes to help pharma reps stay competitive, compliant, and ahead of an industry that never stops changing.